Skip to content

Dental Appliance for Parkinson's Disease

Evaluating the Effects of a Removable Dental Mouthpiece on Symptoms Associated With Parkinson's

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04082663
Acronym
DAPD
Enrollment
20
Registered
2019-09-09
Start date
2019-09-19
Completion date
2020-02-10
Last updated
2021-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

The investigators are evaluating the immediate effect of a dental mouthpiece on gait and balance among people with Parkinson disease as well as longer-term feasibility use and the effect of the mouthpiece on sleep and quality of life.

Detailed description

The investigators are conducting a pilot study with participants who have been diagnosed with Parkinson disease recruited from the community. Participants will attend one in-person visit and be custom fitted with a dental mouthpiece. Participants will be asked to wear the mouthpiece as much as possible for one month including while sleeping and during the day, except while eating. Participants will be asked to return for a second in-person visit to repeat gait and balance (motor) measures.

Interventions

DEVICEDental Mouthpiece

Participants will complete motor tasks with and without the dental mouthpiece during the in-person baseline visit. They will also be asked to wear the mouthpiece for one month, and complete sleep and quality of life questionnaires before and after wearing the mouthpiece.

Sponsors

Washington University School of Medicine
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

All participants will receive a custom-fitted dental mouthpiece and asked to wear the mouthpiece for one month.

Eligibility

Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* have a diagnosis of idiopathic, typical Parkinson Disease according to the United Kingdom Brain Bank Criteria, Hoehn & Yahr stages 1-3; * stable Parkinson disease medications for the two weeks prior to baseline visit; * be able to walk at least 10 meters at baseline with or without an assistive device; * have their own teeth and/or dentures; * be willing to try to wear a mouthpiece for one month; * are over the age of 30; and * provide written or verbal informed consent.

Exclusion criteria

* pre-existing medical conditions that would inhibit full participation in the study's tasks; * absence of any dentition; * cognitive impairments indicated by Mini Mental Status Exam (MMSE) score of \<24; * freezing of gait which moderately or severely impacts walking; or * current use of an oral appliance (e.g., a dental mouthpiece, retainer, or braces).

Design outcomes

Primary

MeasureTime frameDescription
Changes in Gait VelocityBaseline in-person visitGait velocity will be measured while walking forwards with and without the mouthpiece
Changes in Mini-Balance Evaluation Systems Test (Mini-BESTest)Baseline in-person visitBalance will be measured with the Mini-Balance Evaluation Systems Test (Mini-BESTest) with and without the mouthpiece. The assessment includes 14 items each of which is rated on a three-point scale (2: Normal, 1: Moderate, 0: Severe). The 14 item scores are summed for a total score. The range of scores is 0 to 28, and higher scores indicate better balance function.

Secondary

MeasureTime frameDescription
Changes in Parkinson Disease Sleep ScaleBaseline and One monthIndicators of sleep quality will be measured before and after wearing mouthpiece for one-month. The visual analog scale has 15 commonly reported symptoms associated with sleep disturbance (e.g., overall quality of nights sleep, restlessness, daytime dozing). Participants mark a cross along a 10 cm line labelled worst to best state. Items are scored by measuring the distance along each line to the intersection with the cross in centimeters. Each item score can range from 0 - symptom severe and always experienced to 10 - symptom-free. The items are summed and the maximum cumulative score is 150 (free of all symptoms).
Changes in Parkinson Disease Questionnaire-39Baseline and One monthQuality of life will be measured before and after wearing mouthpiece for one-month. This scale has 39 questions with 5 possible answers (0 = never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always). There are eight dimensions: Mobility questions (q)1-10; Activities of Daily Living q11-16; Emotional well-being q17-22; Stigma q23-26; Social Support q27-29; Cognitive impairment q30-33; Communication q34-36; and Bodily Discomfort q37-39. Dimensions are calculated on a scale of 0 to 100, 0 is no problem at all and 100 is maximum level of a problem. The formula for scoring each dimension: (sum of scores of each question in dimension/4 (max.score per question) x nos. questions in dimension)x100. The formula for a total score (called single index) is sum of dimension scores/8.

Countries

United States

Participant flow

Participants by arm

ArmCount
Dental Mouthpiece
Each participant will be fitted with a maxillary orthotic (mouthpiece). The mouthpiece is fabricated with polyvinyl ethylene acetate which is non-toxic to humans. Dental Mouthpiece: Participants will complete motor tasks with and without the dental mouthpiece during the in-person baseline visit. They will also be asked to wear the mouthpiece for one month, and complete sleep and quality of life questionnaires before and after wearing the mouthpiece.
20
Total20

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse Event6
Overall StudyLost to Follow-up1

Baseline characteristics

CharacteristicDental Mouthpiece
Age, Continuous66.9 years
STANDARD_DEVIATION 9.75
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
19 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Movement Disorders Society - United Parkinson Disease Rating Scale III37.25 scores on a scale
STANDARD_DEVIATION 8.67
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
20 Participants
Region of Enrollment
United States
20 participants
Sex: Female, Male
Female
9 Participants
Sex: Female, Male
Male
11 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 20
other
Total, other adverse events
8 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

Changes in Gait Velocity

Gait velocity will be measured while walking forwards with and without the mouthpiece

Time frame: Baseline in-person visit

ArmMeasureGroupValue (MEAN)Dispersion
Dental MouthpieceChanges in Gait VelocityWITHOUT-Mouthpiece1.10 m/sStandard Deviation 0.24
Dental MouthpieceChanges in Gait VelocityWITH-Mouthpiece1.15 m/sStandard Deviation 0.22
Primary

Changes in Mini-Balance Evaluation Systems Test (Mini-BESTest)

Balance will be measured with the Mini-Balance Evaluation Systems Test (Mini-BESTest) with and without the mouthpiece. The assessment includes 14 items each of which is rated on a three-point scale (2: Normal, 1: Moderate, 0: Severe). The 14 item scores are summed for a total score. The range of scores is 0 to 28, and higher scores indicate better balance function.

Time frame: Baseline in-person visit

ArmMeasureGroupValue (MEAN)Dispersion
Dental MouthpieceChanges in Mini-Balance Evaluation Systems Test (Mini-BESTest)WITHOUT-Mouthpiece19.44 score on a scaleStandard Deviation 3.58
Dental MouthpieceChanges in Mini-Balance Evaluation Systems Test (Mini-BESTest)WITH-Mouthpiece19.28 score on a scaleStandard Deviation 4.06
Secondary

Changes in Parkinson Disease Questionnaire-39

Quality of life will be measured before and after wearing mouthpiece for one-month. This scale has 39 questions with 5 possible answers (0 = never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always). There are eight dimensions: Mobility questions (q)1-10; Activities of Daily Living q11-16; Emotional well-being q17-22; Stigma q23-26; Social Support q27-29; Cognitive impairment q30-33; Communication q34-36; and Bodily Discomfort q37-39. Dimensions are calculated on a scale of 0 to 100, 0 is no problem at all and 100 is maximum level of a problem. The formula for scoring each dimension: (sum of scores of each question in dimension/4 (max.score per question) x nos. questions in dimension)x100. The formula for a total score (called single index) is sum of dimension scores/8.

Time frame: Baseline and One month

ArmMeasureGroupValue (MEAN)Dispersion
Dental MouthpieceChanges in Parkinson Disease Questionnaire-39WITHOUT-Mouthpiece at Baseline18.17 score on a scaleStandard Deviation 9.22
Dental MouthpieceChanges in Parkinson Disease Questionnaire-39One-Month Follow-Up17.34 score on a scaleStandard Deviation 11.09
Secondary

Changes in Parkinson Disease Sleep Scale

Indicators of sleep quality will be measured before and after wearing mouthpiece for one-month. The visual analog scale has 15 commonly reported symptoms associated with sleep disturbance (e.g., overall quality of nights sleep, restlessness, daytime dozing). Participants mark a cross along a 10 cm line labelled worst to best state. Items are scored by measuring the distance along each line to the intersection with the cross in centimeters. Each item score can range from 0 - symptom severe and always experienced to 10 - symptom-free. The items are summed and the maximum cumulative score is 150 (free of all symptoms).

Time frame: Baseline and One month

Population: 2 participants missing data

ArmMeasureGroupValue (MEAN)Dispersion
Dental MouthpieceChanges in Parkinson Disease Sleep ScaleWITHOUT-Mouthpiece at Baseline89.32 score on a scaleStandard Deviation 29.45
Dental MouthpieceChanges in Parkinson Disease Sleep ScaleOne-Month Follow-Up91.68 score on a scaleStandard Deviation 29.94

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026